Interactions of Human Melanocortin 4 Receptor with Nonpeptide and Peptide Agonists,
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Specific interactions of human melanocortin-4 receptor (hMC4R) with its nonpeptide and peptide agonists were studied using alanine-scanning mutagenesis. The binding affinities and potencies of two synthetic, small-molecule agonists (THIQ, MB243) were strongly affected by substitutions in transmembrane alpha-helices (TM) 2, 3, 6, and 7 (residues Glu(100), Asp(122), Asp(126), Phe(261), His(264), Leu(265), and Leu(288)). In addition, a I129A mutation primarily affected the binding and potency of THIQ, while F262A, W258A, Y268A mutations impaired interactions with MB243. By contrast, binding affinity and potency of the linear peptide agonist NDP-MSH were substantially reduced only in D126A and H264A mutants. Three-dimensional models of receptor-ligand complexes with their agonists were generated by distance-geometry using the experimental, homology-based, and other structural constraints, including interhelical H-bonds and two disulfide bridges (Cys(40)-Cys(279), Cys(271)-Cys(277)) of hMC4R. In the models, all pharmacophore elements of small-molecule agonists are spatially overlapped with the corresponding key residues (His(6), d-Phe(7), Arg(8), and Trp(9)) of the linear peptide: their charged amine groups interact with acidic residues from TM2 and TM3, similar to His(6) and Arg(6) of NDP-MSH; their substituted piperidines mimic Trp(9) of the peptide and interact with TM5 and TM6, while the d-Phe aromatic rings of all three agonists contact with Leu(133), Trp(258), and Phe(261) residues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They concluded that the HFRW sequence of NDP-MSH was required to form a β-hairpin-like structure so that the phenyl ring of Phe 7 interacts with the indole ring of Trp 9 (Figure 3B).”
From ACTH Antagonists (2016) · cites this paper as [41]
Citations
Cites
CHARMM: A program for macromolecular energy, minimization, and dynamics calculations
Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J., Swaminathan, S., & Karplus, M. (1983) · Journal of Computational Chemistry · doi:10.1002/jcc.540040211 · Cited by 14,944 · cited 1×
“Final energy minimization of all hMC4R-agonist complexes was performed using the CHARMm (45) potential with ε=10, and using the adopted-basis NewtonRaphson method (50 iterations).”
MethodCrystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637 · cited 2×
“However, among all GPCRs, a crystal structure has been determined only for rhodopsin, and only in its inactive state (23,24).”
BackgroundBallesteros, J. A., & Weinstein, H. (1995) · Methods in Neurosciences · doi:10.1016/s1043-9471(05)80049-7 · Cited by 2,999
Principles of docking: An overview of search algorithms and a guide to scoring functions
Halperin, I., Ma, B., Wolfson, H., & Nussinov, R. (2002) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10115 · Cited by 1,294 · cited 1×
“Finally, ligand docking is a complicated problem (28).”
BackgroundRequirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin
Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W. L., & Khorana, H. G. (1996) · Science · doi:10.1126/science.274.5288.768 · Cited by 1,179 · cited 1×
“First, the active, agonist-bound conformation of GPCRs differs from the inactive state, especially in the position of transmembrane helix (TM) 6 (27).”
BackgroundStructure of Bovine Rhodopsin in a Trigonal Crystal Form
Li, J., Edwards, P. C., Burghammer, M., Villa, C., & Schertler, G. F. X. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.08.090 · Cited by 723 · cited 5×
“However, an experimental structure has been obtained only for the inactive state of bovine rhodopsin with bound inverse agonist, 11cisretinal (23,24).”
BackgroundMethodInfluentialSawyer, T. K., Sanfilippo, P. J., Hruby, V. J., Engel, M. H., Heward, C. B., Burnett, J. B., & Hadley, M. E. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.10.5754 · Cited by 575 · cited 1×
“The slightly different orientation for D-Phe7 relative to its L-enatiomer inside the pocket may be responsible for the greater potency and prolonged activity of NDP-MSH, relative toα-MSH (36,50) and for the larger effect of W258A mutation on the binding affinity and potency ofα-MSH relative to NDP-MSH (37).”
BackgroundGantz, I., & Fong, T. M. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00434.2002 · Cited by 466 · cited 5×
“(MC2R), exocrine secretion (MC5R), energy homeostasis, penile erection (MC3R and MC4R) and many others (1,5,6).”
BackgroundMethodInfluentialSelf-citationAgRP(83-132) Acts as an Inverse Agonist on the Human-Melanocortin-4 Receptor
Nijenhuis, W. A. J. (2001) · Molecular Endocrinology · doi:10.1210/me.15.1.164 · Cited by 406
Hrubu, V. J., Lu, D., Sharma, S. D., de L. Castrucci, A., Kesterson, R. A., Al-Obeidi, F. A., Hadley, M. E., & Cone, R. D. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00018a005 · Cited by 348
Research works printed but not linked: 44
- Wikberg J. E., 2000, Pharmacol. Res. 42, 393−420.
- Haqq A. M., 2003, Biochem. J., 376
- Van der Ploeg L. H., 2002, Proc. Natl. Acad. Sci. U.S.A. 99
- Yeo G. S., 2003, Hum. Mol. Genet. 12, 561−574.
- Tao Y. X., 2003, Endocrinology 144, 4544−4551.
- Nijenhuis W. A., 2001, Mol. Endocrinol. 15, 164−171.
- Chai B. X., 2003, Peptides 24, 603−609.
- Palucki B. L., 2005, Bioorg. Med. Chem. Lett., 15
- Wisse B. E., 2003, Ann. N.Y. Acad. Sci. 994, 275−281.
- Willoughby C. A., 2002, Bioorg. Med. Chem. Lett., 12, 96
- Palczewski K., 2000, Science 289, 739−745.
- Li J., 2004, J. Mol. Biol., 343
- John B., 2003, Nucleic Acids Res. 31, 3982−3992.
- Farrens D. L., 1996, Science 274, 768−770.
- Halperin I., 2002, Proteins 47, 409−443.
- Pogozheva I. D., 1997, Biophys. J. 72
- Fowler C., 2004, Biochemistry 43, 8700−8710.
- Fowler C. B., 2004, Biochemistry 43, 15796−15810.
- Chai B.-X., 2005, Biochemistry 44, 3418−3431.
- Meng E. C., 2001, Trends Pharmacol. Sci. 22, 587−593.
- Karnik S. S., 2003, Trends Endocrinol. Metab. 14, 431−437.
- Hadley M. E., 1981, Science 213, 1025−1027.
- Yang Y.-K., 2000, Biochemistry 39, 14900−14911.
- Yang Y.-K., 1997, J. Biol. Chem., 272
- DeBlasi A., 1989, Trends Pharmacol. Sci. 10, 227−229.
- Sawyer T. K., 1982, Proc. Natl. Acad. Sci. U.S.A. 79
- Obeidi F., 1989, J. Am. Chem. Soc., 111
- Haskell-Luevano C., 1997, J. Med. Chem., 40
- Sawyer T. K., 1980, Proc. Natl. Acad. Sci. U.S.A. 77
- Prusis P., 1995, Biochem. Biophys. Res. Commun. 210, 205−210.
- Hruby V. J., 1995, J. Med. Chem., 38
- Nikiforovich G. V., 1998, Biopolymers 46, 155−167.
- Ying J., 2003, Biopolymers 71, 696−716.
- Cai M., 2004, J. Pept. Res., 63
- Kask A., 1998, Endocrinology 139, 5006−5014.
- Sugg E. E., 1988, Biochemistry 27, 8181−8188.
- Haskell-Luevano C., 2000, Peptides, 21, 57
- Nijenhuis W. A., 2003, Peptides 24, 271−280.
- Yang Y., 2002, J. Biol. Chem., 277
- Holder J. R., 2002, J. Med. Chem., 45
- Herpin T. F., 2003, Chem. 46, 1123−1126.
- Pan K., 2003, Chem. 11, 185−192.
- Richardson T. I., 2004, J. Med. Chem, 47
- Ballesteros J. A., 1995, Methods Neurosci. 25, 366−428.
Cited by
The Melanocortin-4 Receptor: Physiology, Pharmacology, and Pathophysiology
Tao, Y.-X. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0037 · Cited by 531
“identify how THIQ binds to the MC4R (326, 353, 354).”
BackgroundMutations in ligands and receptors of the leptin–melanocortin pathway that lead to obesity
Farooqi, I. S., & O'Rahilly, S. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0966 · Cited by 291
“Neuropeptide ligands bind to the cavity within the transmembrane bundle and so result in a conformational change and receptor activation”
BackgroundStructure, function and regulation of the melanocortin receptors
Yang, Y. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.12.020 · Cited by 139
“Mutation of these residues to alanine resulted in significantly decrease in endogenous agonist binding and receptor signaling, suggesting that these residues are also involved in melanocortin orthosteric binding (Fleck et al., 2005; Haskell-Luevano et al., 2001; Nickolls et al., 2003; Pogozheva et al., 2005; Yang et a…”
BackgroundInfluentialTargeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction
Wikberg, J. E. S., & Mutulis, F. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2331 · Cited by 139
“Basis for ligand binding Much attention has been given to computational molecular modelling of the melanocortin receptors, but the results are contradictory as the melanocortin binding pocket was placed at grossly different locations in different studie”
ResultEvolution of POMC: origin, phylogeny, posttranslational processing, and the melanocortins
Dores, R. M., & Baron, A. J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05928.x · Cited by 127
Metadata
- Authors
- Pogozheva, I. D., Chai, B.-X., Lomize, A. L., Fong, T. M., Weinberg, D. H., Nargund, R. P., Mulholland, M. W., Gantz, I., & Mosberg, H. I.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-08-01
- Volume
- 44
- Issue
- 34
- Pages
- 11329-11341
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- PMC
- PMC2532597
- OpenAlex
- W1995624852
- Cited by
- 92
- References
- 81
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 8 · 2016: 4 · 2015: 4 · 2014: 7 · 2013: 7 · 2012: 7
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Michigan
- National Institute on Drug Abuse (R01DA003910, DA03910)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933, P30 DK 34933, R01DK054032, DK054032)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- melanocortin-4 receptor, ligand-receptor interactions, peptide agonists, NDP-MSH, alanine scanning, transmembrane helices, disulfide bonds, pharmacophore, binding affinity, agonist potency
- MeSH terms
- Cyclic AMP, Amino Acid Sequence, Binding Sites, Humans, Models, Molecular, Molecular Sequence Data, Peptides, Piperazines, Piperidines, Recombinant Proteins, Rhodopsin, Transfection, Mutagenesis, Site-Directed, Sequence Alignment, Sequence Homology, Amino Acid, Protein Structure, Secondary, Receptor, Melanocortin, Type 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interactions of Human Melanocortin 4 Receptor with Nonpeptide and Peptide Agonists,. https://app.cochat.ai/papers/10.1021/bi0501840
- The paper
- Pogozheva, I. D., Chai, B.-X., Lomize, A. L., Fong, T. M., Weinberg, D. H., Nargund, R. P., Mulholland, M. W., Gantz, I., & Mosberg, H. I. (2005). Interactions of Human Melanocortin 4 Receptor with Nonpeptide and Peptide Agonists,. Biochemistry. https://doi.org/10.1021/bi0501840
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.